Kapil N. Bhalla

34.3k total citations · 5 hit papers
378 papers, 26.0k citations indexed

About

Kapil N. Bhalla is a scholar working on Molecular Biology, Hematology and Genetics. According to data from OpenAlex, Kapil N. Bhalla has authored 378 papers receiving a total of 26.0k indexed citations (citations by other indexed papers that have themselves been cited), including 253 papers in Molecular Biology, 179 papers in Hematology and 88 papers in Genetics. Recurrent topics in Kapil N. Bhalla's work include Acute Myeloid Leukemia Research (107 papers), Histone Deacetylase Inhibitors Research (89 papers) and Protein Degradation and Inhibitors (72 papers). Kapil N. Bhalla is often cited by papers focused on Acute Myeloid Leukemia Research (107 papers), Histone Deacetylase Inhibitors Research (89 papers) and Protein Degradation and Inhibitors (72 papers). Kapil N. Bhalla collaborates with scholars based in United States, Germany and Switzerland. Kapil N. Bhalla's co-authors include Ana Maria Ibrado, Warren Fiskus, Tsung-I Peng, Jie Yang, Dean P. Jones, Xuesong Liu, Jiyang Cai, Xiaodong Wang, Peter Atadja and Ramadevi Nimmanapalli and has published in prestigious journals such as Science, New England Journal of Medicine and Proceedings of the National Academy of Sciences.

In The Last Decade

Kapil N. Bhalla

357 papers receiving 25.4k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Prevention of Apoptosis by Bcl-2: Release of Cytochrome c from Mitochondria Blocked

1997 4.3k citations Kapil N. Bhalla et al. profile →
Nilotinib in Imatinib-Resistant CML and Philadelphia Chromosome–Positive ALL

2006 970 citations Hagop M. Kantarjian, Kapil N. Bhalla et al. profile →
Inhibition of Glycolysis in Cancer Cells: A Novel Strategy to Overcome Drug Resistance Associated with Mitochondrial Respiratory Defect and Hypoxia

2005 699 citations Kapil N. Bhalla, Peng Huang et al. Cancer Research profile →
Inhibition of Histone Deacetylase 6 Acetylates and Disrupts the Chaperone Function of Heat Shock Protein 90

2005 644 citations Warren Fiskus, Peter Atadja et al. profile →
Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome–positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance

2007 540 citations Hagop M. Kantarjian, Kapil N. Bhalla et al. Blood profile →

Peers

Countries citing papers authored by Kapil N. Bhalla

Since Specialization

Citations

This map shows the geographic impact of Kapil N. Bhalla's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kapil N. Bhalla with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kapil N. Bhalla more than expected).

Fields of papers citing papers by Kapil N. Bhalla

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kapil N. Bhalla. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kapil N. Bhalla. The network helps show where Kapil N. Bhalla may publish in the future.

Co-authorship network of co-authors of Kapil N. Bhalla

This figure shows the co-authorship network connecting the top 25 collaborators of Kapil N. Bhalla. A scholar is included among the top collaborators of Kapil N. Bhalla based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Kapil N. Bhalla. Kapil N. Bhalla is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Preclinical activity of investigational menin inhibitor DSP-5336 (Enzomenib)-based combinations against MLL1-rearranged (MLL-r) or mutant-NPM1 AML models 2025 ·Blood ·Warren Fiskus, Christopher P. Mill, Christine Birdwell, John A. Davis, (unknown), (unknown), Surbhi Sharma, Steven L. Warner, (unknown), Alicia K. Matthews, (unknown), Tapan M. Kadia, Courtney D. DiNardo, Naval Daver, Kapil N. Bhalla	0
2	Serum Resistin as a Potential Mortality Predictor in Neonatal Sepsis 2024 ·Cureus ·(unknown), (unknown), (unknown), Kapil N. Bhalla, (unknown), Naman Jain, (unknown)	1
3	ASXL1 Mutations in AML Are Associated with a Distinct Epigenetic State Which Highlights Vulnerabilities to Specific Epigenetic-Targeted Agents 2024 ·Blood ·Christopher P. Mill, Warren Fiskus, Christine Birdwell, John A. Davis, (unknown), (unknown), Surbhi Sharma, Koji Sasaki, Sanam Loghavi, Tapan M. Kadia, Naval Daver, Courtney D. DiNardo, Lu Wang, Kapil N. Bhalla	1
4	Targeting of epigenetic co-dependencies enhances anti-AML efficacy of Menin inhibitor in AML with MLL1-r or mutant NPM1 2023 ·Blood Cancer Journal ·Warren Fiskus, Christopher P. Mill, Christine Birdwell, John A. Davis, (unknown), Steffen Boettcher, Tapan M. Kadia, Courtney D. DiNardo, Koichi Takahashi, Sanam Loghavi, Michael Soth, Tim Heffernan, Gerard M. McGeehan, Xinjia Ruan, Xiaoping Su, Christopher R. Vakoc, Naval Daver, Kapil N. Bhalla	33
5	Effective Menin inhibitor-based combinations against AML with MLL rearrangement or NPM1 mutation (NPM1c) 2022 ·Blood Cancer Journal ·Warren Fiskus, Steffen Boettcher, Naval Daver, Christopher P. Mill, Koji Sasaki, Christine Birdwell, John A. Davis, Koichi Takahashi, Tapan M. Kadia, Courtney D. DiNardo, Qi Jin, Yuan Qi, Xiaoping Su, Gerard M. McGeehan, Joseph D. Khoury, Benjamin L. Ebert, Kapil N. Bhalla	73
6	Implications of RAS mutational status in subsets of patients with newly diagnosed acute myeloid leukemia across therapy subtypes 2022 ·American Journal of Hematology ·(unknown), Kunhwa Kim, Rashmi Kanagal‐Shamanna, Gautam Borthakur, Guillermo Montalban‐Bravo, Naval Daver, Courtney D. DiNardo, Nicholas J. Short, Musa Yılmaz, Naveen Pemmaraju, Koichi Takahashi, Elias Jabbour, Sherry Pierce, Marina Konopleva, Kapil N. Bhalla, Guillermo Garcia‐Manero, Farhad Ravandi, Hagop M. Kantarjian, Tapan M. Kadia	17
7	Clonal evolution and treatment outcomes in hematopoietic neoplasms arising in patients with germline RUNX1 mutations 2020 ·American Journal of Hematology ·Curtis A. Lachowiez, Sarah A. Bannon, Sanam Loghavi, Feng Wang, Rashmi Kanagal‐Shamanna, Rohtesh S. Mehta, Naval Daver, Gautam Borthakur, Naveen Pemmaraju, Farhad Ravandi, Keyur P. Patel, Guillermo Garcia‐Manero, Koichi Takahashi, Hagop M. Kantarjian, Kapil N. Bhalla, Courtney D. DiNardo	3
8	SIRT2 Deacetylates and Inhibits the Peroxidase Activity of Peroxiredoxin-1 to Sensitize Breast Cancer Cells to Oxidant Stress-Inducing Agents 2016 ·Cancer Research ·Warren Fiskus, Veena Coothankandaswamy, Jianguang Chen, Hongwei Ma, Kyungsoo Ha, Dyana T. Saenz, Stephanie Krieger, Christopher P. Mill, Baohua Sun, Peng Huang, Jeff S. Mumm, Ari Melnick, Kapil N. Bhalla	57
9	Highly Active Combination of BRD4 Antagonist and Histone Deacetylase Inhibitor against Human Acute Myelogenous Leukemia Cells 2014 ·Molecular Cancer Therapeutics ·Warren Fiskus, Sunil Sharma, Jun Qi, John A. Valenta, (unknown), Bhavin Shah, (unknown), Bryce P. Portier, Melissa Rodríguez, Santhana G.T. Devaraj, Ming Zhan, Jianting Sheng, Swaminathan P. Iyer, James E. Bradner, Kapil N. Bhalla	155
10	BET Protein Antagonist JQ1 Is Synergistically Lethal with FLT3 Tyrosine Kinase Inhibitor (TKI) and Overcomes Resistance to FLT3-TKI in AML Cells Expressing FLT-ITD 2014 ·Molecular Cancer Therapeutics ·Warren Fiskus, Sunil Sharma, Jun Qi, Bhavin Shah, Santhana G.T. Devaraj, Christopher Leveque, Bryce P. Portier, Swaminathan P. Iyer, James E. Bradner, Kapil N. Bhalla	112
11	Auranofin Induces Lethal Oxidative and Endoplasmic Reticulum Stress and Exerts Potent Preclinical Activity against Chronic Lymphocytic Leukemia 2014 ·Cancer Research ·Warren Fiskus, Nakhle S. Saba, Min Shen, Mondana Ghias, Jinyun Liu, Soumyasri Das Gupta, Lata Chauhan, Rekha Rao, Sumedha Gunewardena, (unknown), Christopher P. Austin, Kami J. Maddocks, John C. Byrd, Ari Melnick, Peng Huang, Adrian Wiestner, Kapil N. Bhalla	198
12	First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors 2013 ·Clinical Cancer Research ·Cristiana Sessa, Geoffrey I. Shapiro, Kapil N. Bhalla, Carolyn D. Britten, (unknown), Monica Mita, Vali Papadimitrakopoulou, (unknown), Thomas A. Samuel, Mikhail Akimov, Cornelia Quadt, (unknown), Hong Lü, Stuart Bailey, (unknown), Udai Banerji	119
13	Dual PI3K/AKT/mTOR Inhibitor BEZ235 Synergistically Enhances the Activity of JAK2 Inhibitor against Cultured and Primary Human Myeloproliferative Neoplasm Cells 2013 ·Molecular Cancer Therapeutics ·Warren Fiskus, Srđan Verstovšek, Taghi Manshouri, (unknown), (unknown), Sunil Abhyankar, Joseph P. McGuirk, Kapil N. Bhalla	83
14	Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells 2012 ·Clinical Cancer Research ·Warren Fiskus, Rekha Rao, Ramesh Balusu, Siddhartha Ganguly, Jianguo Tao, Eduardo M. Sotomayor, Uma Mudunuru, (unknown), Stacey L. Hembruff, Peter Atadja, Víctor E. Márquez, Kapil N. Bhalla	40
15	Combination of Pan-Histone Deacetylase Inhibitor and Autophagy Inhibitor Exerts Superior Efficacy against Triple-Negative Human Breast Cancer Cells 2012 ·Molecular Cancer Therapeutics ·Rekha Rao, Ramesh Balusu, Warren Fiskus, Uma Mudunuru, Sreedhar Venkannagari, Lata Chauhan, (unknown), Stacey L. Hembruff, Kyungsoo Ha, Peter Atadja, Kapil N. Bhalla	96
16	Heat Shock Protein 90 Inhibitor Is Synergistic with JAK2 Inhibitor and Overcomes Resistance to JAK2-TKI in Human Myeloproliferative Neoplasm Cells 2011 ·Clinical Cancer Research ·Warren Fiskus, Srđan Verstovšek, Taghi Manshouri, Rekha Rao, Ramesh Balusu, Sreedhar Venkannagari, (unknown), Kyungsoo Ha, (unknown), Stacey L. Hembruff, Sunil Abhyankar, Joseph P. McGuirk, Kapil N. Bhalla	83
17	Hsp90 Inhibitor–Mediated Disruption of Chaperone Association of ATR with Hsp90 Sensitizes Cancer Cells to DNA Damage 2011 ·Molecular Cancer Therapeutics ·Kyungsoo Ha, Warren Fiskus, Rekha Rao, Ramesh Balusu, Sreedhar Venkannagari, (unknown), Kapil N. Bhalla	64
18	Role of Acetylation and Extracellular Location of Heat Shock Protein 90α in Tumor Cell Invasion 2008 ·Cancer Research ·Yonghua Yang, (unknown), Jie Shen, Yun Tang, Warren Fiskus, John Nechtman, Peter Atadja, Kapil N. Bhalla	187
19	Anoikis, Initiated by Mcl-1 Degradation and Bim Induction, Is Deregulated during Oncogenesis 2007 ·Cancer Research ·Nicholas T. Woods, Hirohito Yamaguchi, Francis Y. Lee, Kapil N. Bhalla, Hong‐Gang Wang	87
20	Molecular and Cellular Basis for the Anti‐Proliferative Effects of the HDAC Inhibitor LAQ824 2004 ·Novartis Foundation symposium ·Peter Atadja, Meier Hsu, Paul Kwon, (unknown), Kapil N. Bhalla, Stacy Remiszewski	29

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact